Table 2.
Number and Prevalence of Type-Specific High-Risk Human Papillomavirus (HR-HPV) Infections Detected in Oral Rinses at Diagnosis and After Treatment
| Timeframe of Oral Rinse Collection |
Total No. of Participants With Oral Rinses |
DNA Detected | |||||
|---|---|---|---|---|---|---|---|
| HPV16 | Other HR-HPVa | Any HR-HPVb | |||||
| Infections, No. |
Participants, No. (%) |
Infections, No. |
Participants, No. (%) |
Infections, No. |
Participants, No. (%) |
||
| Diagnosis | 124 | 67 | 67 (54) | 28 | 27 (22) | 95 | 80 (65) |
| Posttreatment | |||||||
| Postdiagnosis, mo | |||||||
| 9-12c | 113 | 4 | 4 (4) | 20 | 16 (14) | 24 | 20 (18) |
| 18-24d | 89 | 3 | 3 (3) | 9 | 9 (10) | 12 | 12 (14) |
| Any time | 124 | 6 | 6 (5) | 21 | 17 (14) | 27 | 22 (18) |
| Persistently detected | 5 | 5 (4) | 7 | 7 (6) | 12 | 12 (10) | |
| Newly detected | 1 | 1 (1) | 14 | 12 (10) | 15 | 13 (11) | |
| Cleared after treatmente | 124 | 62 | 62 (93) | 21 | 20 (74) | 83 | 68 (85) |
Abbreviation: HPV16, human papillomavirus type 16.
HR-HPV not including HPV16.
Any HR-HPV, including HPV16.
Participants with an oral rinse from either the 9-month and/or the 12-month (after diagnosis) study visit were included (n = 113): 58 had both 9- and 12-month oral rinses (all concordant), 18 had only 9-month and 37 participants had only 12-month oral rinses.
Participants with an oral rinse from either the 18-month and/or the 24-month (after diagnosis) study visit were included (n = 89): 45 had both 18- and 24-month oral rinses (all concordant), 17 had only 18-month and 27 had only 24-month oral rinses.
Defined as detection of HR-HPV DNA in oral rinse at diagnosis but not in any posttreatment oral rinse.